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ABSTRACT
The T-box transcription factor Brachyury is expressed in a number of tumour 
types and has been demonstrated to have cancer inducing properties. To date, it has 
been linked to cancer associated induction of epithelial to mesenchymal transition, 
tumour metastasis and expression of markers for cancer stem-like cells. Taken 
together, these findings indicate that Brachyury plays an important role in the 
progression of cancer, although the mechanism through which it functions is poorly 
understood. Here we show that Brachyury regulates the potential of Brachyury-
positive colorectal cancer cells to proliferate and reduced levels of Brachyury result in 
inhibition of proliferation, with features consistent with the cells entering a quiescent-
like state. This inhibition of proliferation is dependent upon p27Kip1 demonstrating that 
Brachyury acts to modulate cellular proliferative fate in colorectal cancer cells in a 
p27Kip1-dependent manner. Analysis of patient derived colorectal tumours reveals a 
heterogeneous localisation of Brachyury (in the nucleolus, nucleus and cytoplasm) 
indicating the potential complexity of the regulatory role of Brachyury in solid 
colorectal tumours. 
INTRODUCTION
Brachyury (T) is a developmentally regulated T-box 
transcription factor involved in controlling cell movements 
and differentiation [1–3]. Brachyury expression has been 
detected in various cancers including chordoma [4], lung 
and colon carcinomas [5], where Brachyury protein in 
the cytoplasm has been linked to high tumour grade and 
poor prognosis [4, 5]. The role of Brachyury in tumour 
development is not well understood but it has been shown 
to induce epithelial to mesenchymal transition (EMT) [6], 
impose a survival advantage to lung cancer cells [7] and 
is also linked to the acquisition of properties of cancer 
stem-like cells (CSCs) [8]. A recent study in chordoma 
cell lines demonstrated that Brachyury-depletion resulted 
in G1 growth arrest, through an unknown mechanism, 
and it was postulated that Brachyury might be a master 
regulator controlling an oncogenic transcriptional network 
[9, 10]. Decreased Brachyury has also been shown to lead 
to decreased cell proliferation, migration and invasion in 
mice [11].
p27Kip1 (encoded by the CDKN1B gene) is a 
member of the Cip/Kip family of cyclin-dependent kinase 
inhibitors (CKI) which have well-described nuclear-
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associated tumour suppressor functions in causing G1 
cell-cycle phase arrest [12–14]. Evidence also shows 
a role for p27Kip1 in maintaining genomic integrity in 
the gastrointestinal tissue of mice through control of 
the transition of G2/M in response to DNA damage by 
genotoxic agents [15]. Consistent with this, p27KIP is 
an inhibitor of gastrointestinal tumourigenesis in mice 
[16] and the tumour suppressor functions associated 
with p27Kip1 may be mediated by inhibition of cell-cycle 
progression beyond G1 and maintenance of genomic 
stability in G2/M. In accordance with a function in tumour 
suppression, loss of p27Kip1 in tumour cells is associated 
with a higher tumour grade and poor prognosis [17–21]. 
p27Kip1 also acts as a multi-functional regulator, and 
has cyclin-CDK inhibitor-independent functions (linked 
to its localisation), being involved in alteration of actin 
dynamics and migration [22–24] and in the control of cell 
differentiation, acting as a key cell-cycle to differentiation 
determinant [25–27]. p27Kip1 has been shown to be 
regulated by cMYC at the level of both protein and mRNA 
[25, 28–31]. cMYC is a major oncogenic driver and has 
diverse roles in regulation of cell proliferation, growth, 
apoptosis, metabolism and differentiation [32].
Here, we show that reduction in the levels of 
Brachyury in colorectal cancer (CRC) cells perturbs 
proliferation through a mechanism which involves p27Kip1 
and induces a quiescent-like state from which the cells can 
recover when grown under suitable growth conditions. 
Our results place cMYC downstream of Brachyury and 
suggest that Brachyury modulates the proliferative fate 
of cells. In studies of patient-derived CRC material a 
complex relationship between Brachyury and p27Kip1 is 
revealed, based on heterogeneous localisation patterns of 
Brachyury within the carcinoma. Brachyury is localised 
to a region of the nucleus, consistent with the nucleolus, 
and/or the cytoplasm of some, but not all the cells in the 
carcinoma, suggesting region specific functions within the 
tumour.
RESULTS
Brachyury maintains proliferation of CRC cells
We were interested to determine whether Brachyury 
affects proliferation of CRC cells. We used the Brachyury 
positive CRC cell line, SW480, to derive colonospheres 
(potentially enriched for cancer progenitor cells), and 
carried out an extreme limiting dilution assay (ELDA) [34] 
to determine the ability of single CRC cells to proliferate 
and form spheres in the presence of Brachyury or under 
conditions of siRNA-induced Brachyury-depletion. Single 
Brachyury-depleted CRC cells were 20-fold reduced in 
Figure 1: The effect of Brachyury on colorectal cancer cell proliferation as determined by Extreme limiting dilution 
analysis (ELDA) a) ELDA of colonosphere forming frequency of SW480 CRC cells. Colonospheres derived from 1, 10, 100 
or 1000 CRC cells (per well) were transfected with negative control, Hs_T_8 or Hs_T_5 Brachyury siRNA or hiperfect only, to determine 
the effect on frequency of sphere formation. Column bars on the graph represent the sphere forming frequencies shown in the table 
beneath. Brachyury-knockdown levels were routinely around 80% knockdown as assessed by qRT-PCR. CI = confidence interval. Single 
Brachyury-depleted cells were 20-fold reduced in their sphere forming ability compared to controls. The frequency of sphere forming cells 
was determined using the ELDA web tool at http://bioinf.wehi.edu.ac/software/elda. The number of wells used and data for each dilution 
of cells is shown in figure S1. b) Example of spheres formed from single SW480 colorectal cancer cells after 10 days with non-interfering 
siRNA (control conditions) c) Example of single SW480 colorectal cancer cells that remain in culture after 10 days treatment with siRNA 
to Brachyury (Hs_T_8 or Hs_T_5) , the black arrow points to a single cell (x10 magnification). 
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their ability to form colonospheres and to proliferate, 
compared to controls (Figure 1a, S1). In the presence of 
Brachyury (controls) spheres are formed from single CRC 
cells (Figure 1b). However, when Brachyury levels are 
reduced, the single cells that are plated for the proliferation 
assay remain morphologically unchanged for the duration 
of the experiment (Figure 1c). The reduced number of 
spheres formed following Brachyury-knockdown is 
neither due to apoptosis or senescence (S2). In accordance 
with these observations, the inhibition of proliferation 
following reduction of Brachyury was reversible, and 
when Brachyury-knockdown single cells were transferred 
to fresh media they recovered and formed spheres at a 
frequency of around 30-40%, suggesting that reduced 
levels of Brachyury result in a recoverable, quiescent-like 
state in the CRC cells.
Brachyury regulates cell-cycle modulators cMYC 
and p27Kip1 
We determined whether changes in components of 
cell-cycle regulatory pathways might be responsible for 
the cell proliferation-inhibition phenotype we observed 
following Brachyury-knockdown. Brachyury-knockdown 
in CRC cells (grown as spheres) had a profound negative 
effect on their ability to proliferate (Figure 1a,c); therefore 
we additionally carried out these studies on cells grown 
as adherent monolayers which could be grown more 
easily in larger amounts to obtain sufficient biomaterial 
to study regulatory mechanisms. Cells grown as spheres 
or monolayers expressed similar levels of Brachyury, 
indicating that results for CRC cells grown as spheres or 
monolayers should be comparable (S3a). We observed a 
consistent down-regulation of cMYC (mRNA and protein) 
following Brachyury-knockdown and a corresponding 
decrease in levels of cylcin D2 (CCND2), a known target 
of cMYC [37] (Figure 2a,b). Cyclin D2 complexes with 
CDK4 to control cell division by hyper-phosphorylating 
retinoblastoma (Rb) leading to its inactivation [38]. 
However, we see no change in the levels of either 
phospho-Rb or unphosphorylated-Rb making it unlikely 
that the growth inhibitory effects observed in these cells 
occurs through inactivation of Rb (Figure 2b). Following 
activation of cMYC, cyclin D2 (in a complex with CDK4) 
Figure 2: Reduced levels of Brachyury result in increased levels of p27Kip1 a) qRT-PCR analysis showing change in expression 
levels of the panel of genes in response to siRNA knockdown of Brachyury in SW480 cells b) Western blot analysis showing changes in 
levels of proteins in response to siRNA knockdown of Brachyury in SW480 cells (Western blot images have been cropped for size and 
are representative of three repeats). Densitometry measurements for p27Kip1 are shown in S3b and reveal a two-fold increase. c) qRT-
PCR analysis of p27Kip1 expression levels in response to siRNA knockdown of Brachyury in H460 cells. Results of qRT-PCR analysis 
were normalised to a combination of three endogenous reference genes (GAPDH, β-actin and lamin A/C) and the relative fold change in 
expression was computed by the ΔΔCt method. Error bars show standard error of the mean. 
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has been shown to sequester p27Kip1, thereby limiting its 
cell-cycle inhibitory activity [37]. On depleting Brachyury 
we observed an increase in the levels of p27Kip1 protein 
(Figure 2b and S3b) consistent with the decreased 
levels of cyclin D2 relieving the repression of p27Kip1, 
but also observed an increase in the level of expression 
of the CDKN1B gene suggesting that Brachyury might 
regulate the levels of p27Kip1 at a transcriptional level, 
independently of sequestration by cyclin D2 (Figure 2a). 
Brachyury-knockdown in the lung carcinoma cell line, 
H460, showed a similar effect of increasing the levels 
and expression of p27Kip1 (Figure 2c), indicating that the 
negative regulation of p27Kip1 by Brachyury may be a 
universal mechanism in different Brachyury-expressing 
tumour cell types.
Analysis of SW480 cells transfected with Brachyury 
shRNA expressing vectors revealed elongated mean cell 
doubling times (Figure 3, S4). The elongated cell-cycle 
of transfected cells (GFP-gated) was concomitant with 
increased lengths of S and G2 phases (1.8 times times 
longer in S phase and 3.4 times longer in G2 compared to 
controls) (S4).
Inhibition of proliferation is dependent upon 
p27Kip1
Given the increase in expression levels of p27Kip1 
following Brachyury-knockdown, and the reported 
ability of p27Kip1 to regulate self-renewal of human (h)ES 
cells [39], we carried out the cell proliferation assay on 
CRC cells (grown from single cells) under conditions of 
Brachyury and p27Kip1 double knockdown, to determine 
whether simultaneous p27Kip1 reduction could rescue the 
inhibition of proliferation observed in single Brachyury-
knockdown cells. Under these conditions, single CRC cells 
formed spheres close to frequencies of non-interfering 
control cells (Figure 4a, S5), suggesting that inhibition of 
p27Kip1 may be the predominant pathway through which 
Brachyury controls CRC cell proliferation. Rescue by 
p27Kip1-reduction could be achieved either by simultaneous 
knockdown alongside Brachyury-knockdown, or 
following a prior induction of Brachyury proliferation 
arrest, to induce the quiescent-like state (using siRNA-
Brachyury), followed by subsequent knockdown of p27Kip1 
at two different time points (Figure 4b-h and S5); both 
result in proliferative rescue.
Decreased levels of cMYC were observed following 
Brachyury-knockdown and so we determined whether 
similar effects of cell proliferation arrest and induction of 
a quiescent-like state were imposed following reduction 
of cMYC or in combination with p27Kip1. As before, we 
carried out a cell proliferation assay on CRC cells, firstly, 
under conditions of cMYC-knockdown. We observed 
a reduction in the sphere-forming frequency of CRC 
cells (around a 15 fold reduction in spheres compared 
to controls spheres) (Figure 5). We then performed 
cMYC/p27KIP double knockdown to determine whether 
p27Kip1 could rescue the inhibition of proliferation 
observed in single cMYC-knockdown cells. Whilst 
simultaneous cMYC/p27Kip1 double knockdown rescues 
cell proliferation, prior treatment of the cells with cMYC-
siRNA followed by treatment with p27Kip1-siRNA could 
not rescue the negative proliferation effect (Figure 5, S6). 
In contrast to the results with Brachyury, the cells did 
not appear to be in a state of quiescence and could not 
be recovered, suggesting that Brachyury modulates cell 
proliferation, possibly in a distinct manner from cMYC. 
Brachyury affects expression of cell-cycle 
regulatory genes
We wanted to further understand the molecular 
detail of cells with reduced Brachyury and so carried out 
RNA-seq analysis on control CRC cells versus siRNA 
Brachyury-knockdown cells. There is a pre-dominant 
down-regulation of genes in Brachyury-knockdown 
cells as revealed by a heat map of the most significantly 
changed genes organized in hierarchical clusters of gene 
expression patterns (S7). Some of the most significantly 
down-regulated genes include those required for 
progression through the cell-cycle such as CDC27, 
CCND2, CCNE1. Confirming our qRT-PCR data, the 
CDKN1B (p27Kip1) gene was up-regulated. Interestingly, 
a cohort of genes associated with transcription were 
also down-regulated, such as TNFRSF12A, POLR3B, 
Figure 3: Growth curves of SW480 cells transfected 
with negative control shRNA vector or Brachyury 
silencing shRNA vector (four different shRNA 
expressing vectors with GFP-selection), compared with 
untreated SW480 cells. Cells transfected with Brachyury 
shRNA expressing vectors revealed elongated cell doubling 
times (from 24.83± 1.2 hours in control cells to 40.24±2.65 hours 
in Brachyury depleted cells, mean ± SD, n=3, P=0.001) (see also 
S4). Error bars denote standard deviation (n=3). The differences 
between the negative control and Brachyury-knockdown were 
significant at P values *P < 0.05 and ***P < 0.001.
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POLR2L, and might reflect the quiescent-like state 
imposed following Brachyury-knockdown which has been 
associated with decreased RNA levels [40]. Significant 
changes were observed for gene ontology (GO) clusters 
(S7: Table 1): these also suggest changes in pathways 
associated with cell-cycle progression, such as S phase 
regulators, DNA strand elongation modulators involved 
in DNA replication, and rRNA processing. Disruption 
of any of these processes could interfere with the normal 
cell division cycle and growth, and the reduced levels of 
RNA may be associated with the induction of quiescence. 
Associated with this, reduction in RNA levels might 
also reflect disrupted nucleolar function in Brachyury-
knockdown cells [41].
Complex distribution of Brachyury in colorectal 
carcinomas
Our data support the notion that Brachyury 
modulates the levels of p27Kip1 in CRC cells and that 
this might be important for regulating the proliferative 
or quiescent potential of cancer cells. Furthermore, GO 
analysis might infer a role for Brachyury consistent with 
RNA processing and cell-cycle control. We therefore 
wanted to compare distribution patterns of Brachyury 
and p27Kip1 in patient-derived CRC specimens by 
immunohistochemistry (IHC). Not all cells within the 
carcinoma give positive staining for Brachyury, but some 
areas displayed distinct nucleolar staining (Figure 6a, b). 
Figure 4: Rescue of Brachyury induced cell proliferation arrest by depletion of p27Kip1 (a) ELDA assay showing 
colonosphere forming frequency of colorectal cancer cells under different conditions; control, Brachyury single knockdown, 
p27Kip1 single knockdown and Brachyury/ p27Kip1 double knockdowns (1, 2 and 3 doses of siRNA). Column bars on the graph 
represent the sphere forming frequencies shown in the table beneath; Brachyury-knockdown cells form spheres at frequencies as low as 
1:44 cells. Brachyury and p27Kip1 knockdown levels were routinely around 80% as assessed by qRT-PCR. CI = confidence interval. The 
frequency of sphere forming cells was determined using the ELDA web tool at http://bioinf.wehi.edu.ac/software/elda. The number of wells 
used and data for each dilution of cells in the ELDA assay are shown in Figure S4. Examples of single SW480 cells grown for 10 days 
to form spheres are shown in a)-h) under the following conditions b) untreated control cells c) control cells treated with non-interfering 
siRNA d) control cells treated with hiperfect e) cells treated with siRNA to p27Kip1 f) and g) Brachyury siRNA treated cells h) Brachyury 
and p27Kip1 siRNA treated cells. 
Figure 5: Effect of cMyc and p27Kip1 siRNA knockdown on SW480 colorectal cancer cell proliferation a) ELDA of 
colonosphere forming frequency of CRC cells. Colonospheres derived from 1, 10, 100 or 1000 CRC cells/well (SW480) were 
transfected with negative control non-interfering siRNA, hiperfect only control, cMyc siRNA, p27Kip1 siRNA, cMyc and p27Kip1double 
knockdown siRNA to determine the effect on frequency of sphere formation. Column bars on the graph represent the sphere forming 
frequencies shown in the table beneath. CI = confidence interval. The frequency of sphere forming cells was determined using the ELDA 
web tool at http://bioinf.wehi.edu.ac/software/elda b) qRT-PCR analysis of gene expression levels under conditions of cMyc, p27Kip1 and 
cMyc/ p27Kip1 double knockdown. The number of wells used and data for each dilution of cells is shown in Figure S6.
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To our knowledge, this is the first report of this staining 
pattern for Brachyury. We also observed widespread 
cytoplasmic staining of Brachyury in accordance with 
observations by Kilic and co-workers [4]. Whilst the 
carcinoma was also strongly positive for the proliferation 
marker Ki67, it only displayed p27Kip1 staining at the 
tumour margin (Figure 6c-f). In summary, the carcinoma 
revealed heterogeneity of Brachyury localization, stained 
positive for Ki67, but p27Kip1 staining was only observed 
at the margin. The heterogeneity of Brachyury distribution 
in the tumour suggests that it may have region specific 
functions.
DISCUSSION
We report that Brachyury modulates cancer cell 
proliferation through a p27Kip1-dependent mechanism. 
When Brachyury levels are reduced, proliferative arrest 
ensues and a quiescent-like state is adopted from which 
cells can reversibly recover under suitable growth 
conditions. This suggests that inhibition of p27KIP is a 
major route through which Brachyury functions to allow 
proliferation, since double knockdown of Brachyury and 
p27Kip1 results in restoration of cell proliferation. The 
effects of Brachyury on p27Kip1 might be due to cMYC; 
whilst cMYC-knockdown induces proliferation arrest, 
there is a difference in the response to Brachyury since 
cells do not enter a quiescent-like state (as defined by 
ability to re-enter the cell-cycle). Simultaneous reductions 
in p27Kip1 and cMYC rescue the proliferation defect, 
however, the arrest imposed by reduced cMYC can 
only be relieved by simultaneous knockdown of p27Kip1 
and not if p27Kip1 is depleted after prior growth arrest by 
cMYC-knockdown. The difference in responses between 
Brachyury/p27Kip1 and cMYC/p27Kip1 double knockdowns 
may be due to dosage of cMYC. Although reduced, levels 
of cMYC remain relatively high following Brachyury-
knockdown compared to levels of cMYC following cMYC-
knockdown directly. We might speculate that very low 
levels of cMYC (observed in direct cMYC-knockdown) 
exclude the cells from re-entering the cell-cycle, but 
higher levels observed in the Brachyury-knockdown cells 
are ‘just right’ to allow cells to enter a quiescent-like state. 
Evidence in support of this is seen by the fact that one of 
the main routes by which cMYC drives tumourigenesis is 
through inhibition of differentiation and it has been shown 
to antagonize differentiation and growth inhibition effects 
of p27Kip1 in leukaemia cells [42]. 
It is possible that Brachyury acts to regulate both. 
We speculate that the presence of Brachyury results in high 
cMYC/low p27Kip1 allowing proliferation (and avoidance 
of differentiation), but when Brachyury levels are 
reduced, this results in low, or optimal levels of, cMYC/
high p27Kip1 inducing a quiescent-like state, and enabling 
subsequent cell differentiation with appropriate signals. 
Brachyury might impose a state of ‘competence’ to cells, 
allowing decisions to be made between proliferation and 
Figure 6: Immunohistochemistry staining of 
Brachyury and p27Kip1 in a colorectal carcinoma a) and 
b) Brachyury is present in the cytoplasm and nucleolar 
region of the nucleus in a heterogeneous pattern within 
the carcinoma (x2 and x40 respectively); red arrows point 
to nucleolar staining, yellow arrow points to cytoplasmic 
staining and green arrow points to a negative-staining 
cell c) and d) p27Kip1 is predominantly negative within 
the carcinoma except for cells at the margins (x2 and 
x40 respectively) e) and f) Ki67 staining demonstrates 
proliferation of cells within the carcinoma (x2 and x40 
respectively). Four patient samples were studied and all were 
Brachyury positive: the results shown are from a single patient 
and are representative of staining patterns obtained for the four 
Brachyury positive CRC patients.
Figure 7: Schematic model describing a central role for 
Brachyury in regulating proliferation and quiescence.
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quiescence, regulating levels of p27Kip1 as a key effector 
(Figure 7). Interestingly, ChIP-seq experiments performed 
in mouse identified Brachyury binding sites in Myc and 
CDKN1B (p27Kip1) at proximal enhancer elements [43].
Over-expression of p27Kip1 in hES cells leads to 
growth arrest and a decrease in Brachyury, which may be 
linked to regulation of EMT [39]. Increased p27Kip1 is also 
required to maintain terminal differentiation following exit 
from the cell-cycle [44]. Our studies show that Brachyury-
knockdown results in inhibition of proliferation associated 
with an increased cell doubling time, but do not reveal a 
specific cell-cycle stage arrest. Studies in chordoma cells, 
with reduced Brachyury, showed a specific proliferation 
and G1 phase arrest [10]. The elongation/delayed cell 
division times that we observed following Brachyury-
knockdown, and our GO analysis suggests that Brachyury 
might also be linked to cell growth changes in CRC cells. 
Interestingly, neither the response to reduced Brachyury 
in chordomas, nor the response we observe in CRC cells 
complies with studies carried out recently in lung cell lines 
where elevated Brachyury was associated with decreased 
cell proliferation [7]. This may reflect differences inherent 
to the use of different tumour cell types, or to variation in 
control of cell-cycle elements by Brachyury in different 
cell contexts and possibly to different doses, levels or 
compartmentalization of Brachyury. 
High levels of p27Kip1 are found in quiescent cells 
and transcripts are rapidly degraded following mitogenic 
activation in cancer cells [45]. Indeed, levels of p27Kip1 are 
shown to be important for regulating entry into quiescence 
[29] and although levels remain high in quiescent cells, 
there is evidence to suggest that the quiescent state (in 
fibroblasts at least) is only attained by active suppression 
of terminal differentiation [46]. Quiescent cells are 
thought to be ‘poised’, ready to be activated [40] and it 
could be envisaged that this state is vital for progression 
of a tumour to a new site. It remains a question as to 
whether Brachyury is a pre-requisite for cancer cells to 
modify themselves prior to imposition of a quiescent-
like state. Certainly our GO analysis are indicative of 
changes in genes associated with cell-cycle progression, 
DNA replication and RNA processing, in agreement with 
changes that might be observed in the quiescent stem cell 
signature [40]. Furthermore, the intriguing localization 
of Brachyury to the nucleolus suggests a role in rRNA 
processing and/or cell-cycle regulation. 
The sub-cellular localization pattern of Brachyury 
within the carcinoma was complex, possibly reflecting 
a dynamic contribution to diverse functions in the cell, 
indeed, Brachyury was recently suggested to act as a 
master regulator in chordoma cells [10] . 
We note that not all cancer cells require Brachyury 
for proliferation, and, Brachyury may just confer 
‘competence’ to cells to make ‘decisions’ of whether to 
proliferate or leave the cell-cycle and differentiate. We 
also carried out the ELDA assay with the Brachyury-
negative CRC cell line, HCT116, and did not observe 
reduced sphere forming frequencies with Brachyury-
knockdown. This suggests that alternative mechanisms 
governing proliferation exist in different CRC cells. 
Interestingly, HCT116 cells appeared to be nullipotent in 
differentiation assays of CSCs [47] suggesting again, that 
the presence of Brachyury might be required to regulate 
the interface between proliferation and differentiation. 
In accordance, evidence also suggests that Brachyury is 
critical in controlling both cell differentiation and division 
during normal development of the notochord in ascidians 
[48].
Finally, we postulate that ‘fine tuning’ of Brachyury 
levels in a cell could be a mechanism for cancer cells 
to become resistant to chemotherapies: cells would be 
able to ‘drop out’ of proliferation and enter a quiescent-
like state thereby avoiding genotoxic agents targeted at 
dividing cells. Then, when conditions allow, Brachyury 
would be ‘switched’ back on, conferring this same state 
of ‘competence’ and enabling its cancer promoting 
properties.
MATERIALS AND METHODS
Western Blot 
These were carried out as in S9. Primary antibodies 
are listed in S9. 
Quantitative Real-time PCR 
RNA was extracted using RNeasy Plus Mini Kit 
(Qiagen, #74136). First-strand cDNA synthesis used 
Quantitect Reverse Transcription kit (Qiagen, #205310). 
qRTPCR was carried out using CFX96 Real-Time System 
C1000 Thermal Cycler (BioRad) with Quantifast SYBR 
green RT-PCR kit (Qiagen, #204154). The QuantiTect 
Primer Assay (Qiagen) was used for genes listed in S9. 
Cell Culture 
SW480 cells (ECACC, cell line authentication 
report number 710236782) were cultured in DMEM 
medium (Life Technologies, #61965) supplemented 
with 10% fetal calf serum; H460 cells (ECACC, cell line 
authentication report number 710236782) were grown in 
RPMI medium (Life Technologies, #61870) supplemented 
with 10% fetal calf serum. Both cell lines have undergone 
16 loci STR authentication (LGC Standards, UK).
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Transfection
Brachyury siRNA (Qiagen, SI04133521, 
SI00738255), p27Kip1 (Qiagen, SI02621990), cMYC 
(Qiagen, SI00300902) and negative control siRNA 
(Qiagen, 1027280) was used at a final concentration 
of 5 nM. Transfection was carried out with HiPerFect 
Reagent (Qiagen, 301705) according to the manufacturer’s 
instructions. 
Colonosphere Formation Assay
Primary colonospheres were generated as previously 
described [33]. After 5-7 days the colonospheres were 
dissociated to a single cell suspension with Stem Pro 
Accutase (Life Technologies, A11105-01) and sub-
cultured or used for further experiments. 
Extreme limiting dilution analysis 
Extreme limiting dilution analysis (ELDA) was 
performed as described [34] and details are listed in S9. 
FACS 
SW480 cells were transiently transfected with 
GFP-encoding Sure Silencing shRNA plasmid (Qiagen, 
KH02753) using Attractene Transfection Reagent (Qiagen, 
301005). Target sequences for shRNA and FACS analysis 
is described in S9. 
Growth curve analysis 
SW480 cells were plated at equivalent densities 
(1 × 105 cells/ml) in 6-well plates and allowed to attach. 
Transient transfection with shRNA was performed on the 
same day. A second shRNA treatment and media change 
was performed day 3 post-transfection. At daily intervals, 
cells were trypsinized, and 3 wells per condition were 
counted using Biorad’s TC 20 automated cell counter with 
the trypan blue exclusion method.
Immunohistochemistry (IHC)
Samples of human colon cancer were obtained from 
individuals undergoing colonic resection. IHC details are 
described in S9. Antigen retrieval and antibody dilutions 
are listed in S9. 
RNAseq 
RNA isolation, quality control and details of 
RNAseq are described in S9. Fastq data underwent guided 
alignment to the human genome (NCBI Build 37.2) 
using Tophat v2.0.6 [35]. Read duplicates were removed 
using Picard (http://picard.sourceforge.net/) and counts/
gene generated using HTSeq. Differential expression at 
the gene level was carried out using the Bioconductor 
package DESeq [36]. Pathway analysis was carried out on 
significantly differentially expressed genes using TopGO 
package (Bioconductor, http://www.bioconductor.org/
packages/2.12/bioc/html/topGO.html).
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